阿托伐他汀对高血压伴心力衰竭患者心功能的影响被引量：2

下载PDF

导出

摘要他汀类药物具有改善心肌细胞功能、抑制血管平滑肌细胞基质金属蛋白酶（MMPs）表达、抗炎等非调脂作用,成为冠心病一级和二级预防最重要的治疗。本研究旨在探讨阿托伐他汀对高血压伴心力衰竭患者心功能的影响。

作者孙跃玲陈苏涂远超

机构地区湖北省新华医院

出处《内科急危重症杂志》 2011年第1期32-34,共3页 Journal of Critical Care In Internal Medicine

关键词高血压慢性心力衰竭阿托伐他汀左室射血分数

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1Corsini A. Fluvastatin: effects beyond cholesterol lowering. JCardiovasc Pharmacol Ther, 2000, 5: 161.
2Yndestadl A, Damas JK, Oie E, et al. Systemic inflammation inheart failure-The whys and wherefores. Heart Failure Reviews,2006, 11:83.
3Anker SD, Von Haehling S. Inflammatory mediators in chronicheart failure: an overview. Heart, 2004, 90:464.
4Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulnessof atorvastatin in patients with heart failure due to inflammatorydilated cardiomyopathy and elevated cholesterol levels. Am JCardiol, 2006, 97:899.
5Node K, Fujita M, Kitakaze M, et al. Short term statint herapyimproves cardiac function and symptoms in patients with idio-pathic dilated eardiomyopathy. Circulation, 2003, 108 :839.
6席海林,邓学军,赵咏梅.阿托伐他汀对慢性心力衰竭患者心功能及肿瘤坏死因子-α的影响[J].内科急危重症杂志,2007,13(6):289-291. 被引量：3
7Yamazaki T, Lee JD, Shimizu H, et al. Circulating matrix met-alloproteinase-2 is elevated in patients with congestive heart fail-ure. Eur J Heart Fail, 2004, 6:41.
8Nakaya R, Uzui H, et al. Pravaatorvastatin suppresses the in-crease in matrix metallo proteinase-2 levels after acute myocardi-al infarction. Int J Cardiol, 2005,105:67.
9张林叶,邢文,王安才.阿托伐他汀对高血压大鼠心脏血管紧张素转换酶2表达的影响[J].中国动脉硬化杂志,2009,17(5):375-378. 被引量：6

二级参考文献18

1王安才,成蓓,谢晓竟,徐浩.阿托伐他汀对自发性高血压大鼠心室重构的影响[J].中国临床药理学与治疗学,2004,9(8):880-884. 被引量：32
2王安才,成蓓,谢晓竟,徐浩.阿托伐他汀对自发性高血压大鼠血压和心肌血管紧张素Ⅱ1型和2型受体表达的影响[J].中国动脉硬化杂志,2005,13(1):40-44. 被引量：19
3胡珍娉,李大主,胡英锋,杨克平.急性冠脉综合征患者CD4^+CD25^+T调节细胞变化及阿托伐他汀的作用[J].内科急危重症杂志,2007,13(3):118-120. 被引量：2
4Donoghue M, Hsieh F, Baronaz E, et al. A novel angiotensin-eonvertingenryme- related earboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J]. Circ Res, 2000, 87 (5) : E1 - E9.
5Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function [ J]. Nature, 2002, 417 (6 891) : 822-828.
6Crackower MA, Saran R, Oudit GY, et al. Converting enzyme inhibitorsregressed cardiac hypertrophy and reduced tissue angiotensin Ⅱ in SHR [J]. J Hypertens, 1991, 9 (7) : 595-599.
7Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-( 1-7 ) binds to specific receptors on cardiac fibroblasts to initiate antifrbrotie and antitrophic effects[J]. Am J Physiol Heart Circ Physiol, 2005 , 289 (6) : H2 356- 363.
8Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin Ⅱ-induced cardiac remodeling by angiotensin- ( 1-7 ) [J]. Am J Physiol Heart Circ Physiol, 2007, 292 (2) : H736-742.
9Urata H, Healy B, Stewart RW,et al. Anglotensin Ⅱ-forming pathways in normal and failing human hearts [J]. Circ Res, 1990, 66 (4) : 883- 890.
10Huentelman M J, Zubcevic J, Katovich MJ, et al. Cloning and character- izafion of a secreted form of angiotensin-converting enzyme 2 [ J ]. Regul Rept, 2004, 122 (2) : 61-67.